OBJECTIVE: Our objective was to analyze factors predicting outcomes after a total pancreatectomy and islet autotransplantation (TP-IAT). BACKGROUND: Chronic pancreatitis (CP) is increasingly treated by a TP-IAT. Postoperative outcomes are generally favorable, but a minority of patients fare poorly. METHODS: In our single-centered study, we analyzed the records of 581 patients with CP who underwent a TP-IAT. Endpoints included persistent postoperative "pancreatic pain" similar to preoperative levels, narcotic use for any reason, and islet graft failure at 1 year. RESULTS: In our patients, the duration (mean ± SD) of CP before their TP-IAT was 7.1 ± 0.3 years and narcotic usage of 3.3 ± 0.2 years. Pediatric patients had better postoperative outcomes. Among adult patients, the odds of narcotic use at 1 year were increased by previous endoscopic retrograde cholangiopancreatography (ERCP) and stent placement, and a high number of previous stents (>3). Independent risk factors for pancreatic pain at 1 year were pancreas divisum, previous body mass index >30, and a high number of previous stents (>3). The strongest independent risk factor for islet graft failure was a low islet yield-in islet equivalents (IEQ)-per kilogram of body weight. We noted a strong dose-response relationship between the lowest-yield category (<2000 IEQ) and the highest (≥5000 IEQ or more). Islet graft failure was 25-fold more likely in the lowest-yield category. CONCLUSIONS: This article represents the largest study of factors predicting outcomes after a TP-IAT. Preoperatively, the patient subgroups we identified warrant further attention.
OBJECTIVE: Our objective was to analyze factors predicting outcomes after a total pancreatectomy and islet autotransplantation (TP-IAT). BACKGROUND:Chronic pancreatitis (CP) is increasingly treated by a TP-IAT. Postoperative outcomes are generally favorable, but a minority of patients fare poorly. METHODS: In our single-centered study, we analyzed the records of 581 patients with CP who underwent a TP-IAT. Endpoints included persistent postoperative "pancreatic pain" similar to preoperative levels, narcotic use for any reason, and islet graft failure at 1 year. RESULTS: In our patients, the duration (mean ± SD) of CP before their TP-IAT was 7.1 ± 0.3 years and narcotic usage of 3.3 ± 0.2 years. Pediatric patients had better postoperative outcomes. Among adult patients, the odds of narcotic use at 1 year were increased by previous endoscopic retrograde cholangiopancreatography (ERCP) and stent placement, and a high number of previous stents (>3). Independent risk factors for pancreatic pain at 1 year were pancreas divisum, previous body mass index >30, and a high number of previous stents (>3). The strongest independent risk factor for islet graft failure was a low islet yield-in islet equivalents (IEQ)-per kilogram of body weight. We noted a strong dose-response relationship between the lowest-yield category (<2000 IEQ) and the highest (≥5000 IEQ or more). Islet graft failure was 25-fold more likely in the lowest-yield category. CONCLUSIONS: This article represents the largest study of factors predicting outcomes after a TP-IAT. Preoperatively, the patient subgroups we identified warrant further attention.
Authors: Katherine A Morgan; Jeffrey Borckardt; Wendy Balliet; Stefanie M Owczarski; David B Adams Journal: J Am Coll Surg Date: 2015-01-06 Impact factor: 6.113
Authors: Giuseppe Garcea; James Weaver; John Phillips; Cristina A Pollard; Severine C Ilouz; M'balu A Webb; David P Berry; Ashley R Dennison Journal: Pancreas Date: 2009-01 Impact factor: 3.327
Authors: Syed A Ahmad; Andrew M Lowy; Curtis J Wray; David D'Alessio; Kywran A Choe; Laura E James; Andreas Gelrud; Jeffrey B Matthews; Horacio L R Rilo Journal: J Am Coll Surg Date: 2005-09-23 Impact factor: 6.113
Authors: David E R Sutherland; David M Radosevich; Melena D Bellin; Bernard J Hering; Gregory J Beilman; Ty B Dunn; Srinath Chinnakotla; Selwyn M Vickers; Barbara Bland; A N Balamurugan; Martin L Freeman; Timothy L Pruett Journal: J Am Coll Surg Date: 2012-03-06 Impact factor: 6.113
Authors: Julie Dunderdale; John C McAuliffe; Sandre F McNeal; Stacy M J Bryant; Brett D Yancey; Grace Flowers; John D Christein Journal: J Am Coll Surg Date: 2013-04 Impact factor: 6.113
Authors: George K John; Vikesh K Singh; Robert A Moran; Daniel Warren; Zhaoli Sun; Niraj Desai; Christi Walsh; Rita R Kalyani; Erica Hall; Kenzo Hirose; Martin A Makary; Ellen M Stein Journal: J Gastrointest Surg Date: 2017-01-12 Impact factor: 3.452
Authors: Julie R McSwain; Madeline Nykamp; Bethany J Wolf; Jeffrey D McMurray; Christopher A Skorke; Carlee A Clark Journal: Pancreas Date: 2019-02 Impact factor: 3.327
Authors: Lindsey D Bogachus; Elizabeth Oseid; Melena Bellin; Adrian Vella; R Paul Robertson Journal: J Clin Endocrinol Metab Date: 2017-09-01 Impact factor: 5.958
Authors: Bomi Lee; Julia Z Adamska; Hong Namkoong; Melena D Bellin; Josh Wilhelm; Gregory L Szot; David M Louis; Mark M Davis; Stephen J Pandol; Aida Habtezion Journal: J Clin Invest Date: 2020-05-01 Impact factor: 14.808
Authors: Joshua S Jolissaint; Linda W Langman; Claire L DeBolt; Jacob A Tatum; Allison N Martin; Andrew Y Wang; Daniel S Strand; Victor M Zaydfudim; Reid B Adams; Kenneth L Brayman Journal: Clin Transplant Date: 2016-10-17 Impact factor: 2.863